Taig Mac Carthy

Taig Mac Carthy is a serial entrepreneur and a leading figure in the intersection of artificial intelligence and dermatology. As the Chief Operating Officer (COO) and Research Director at Legit.Health, Taig has been instrumental in developing next-generation clinical decision support tools that assist healthcare professionals in the diagnosis and monitoring of skin conditions.

Professional Focus and Innovation
Taig specializes in the creation of software products and medical devices, with a deep focus on compliance and medical computer vision. Under his leadership, Legit.Health has developed groundbreaking AI-driven scoring systems.

His work is centered on transforming traditional, subjective medical assessments into objective, standardized, and rapid evaluations. By leveraging convolutional neural networks, Taig and his team provide clinical insights through simple image analysis, significantly reducing interobserver variability in clinical trials and routine practice.

Impact on Clinical Trials
A recognized expert in the digitalization of clinical endpoints, Taig is a frequent voice on how AI can accelerate drug development. His contributions to the field include:

Reducing Database Lock Timelines: Implementing AI to ensure superior data quality and faster acquisition of endpoints.

Decentralized Clinical Trials (DCT): Enabling remote data capture and teledermatology to improve patient adherence and protocol consistency.

Quality Control: Developing algorithms to prevent the use of low-quality images, ensuring that clinical trials remain robust and FDA/EMA compliant.

Academic and Industry Recognition
Taig is a prolific researcher with numerous publications in peer-reviewed journals such as the Journal of the European Academy of Dermatology and Venereology. He has collaborated with world-renowned dermatologists to validate AI systems that are now used in hospitals across Spain and Europe.

Taig holds a strong commitment to making healthcare more sustainable through efficient triage and supporting patients with rare diseases who are often underserved by traditional healthcare systems.